PARP1 and neoplasm: While PARP1 has emerged as a promising target for overcoming chemoresistance in osteosarcoma, a clinical study demonstrated encouraging anti‐tumor activity when combined with trabectedin in 50 patients,[32] its benefits are not universal due to complex molecular mechanisms.[33] Our study provides a rationale for the use of PARP1 inhibitors in obese patients with osteosarcoma.